FDA approves Mesoblast's cell therapy for graft-versus-host disease

The U.S. Food and Drug Administration on Wednesday approved Mesoblast (NASDAQ:MESO)'s cell therapy for treating a type of complication that occurs after a stem cell or bone marrow transplant called graft-versus-host disease (GVHD).